We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.31% less ownership

Funds ownership: 50.87% → 49.55% (-1.3%)

7% less funds holding

Funds holding: 115 → 107 (-8)

25% less capital invested

Capital invested by funds: $152M → $113M (-$38.5M)

34% less call options, than puts

Call options by funds: $109K | Put options by funds: $164K

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K

Top Buyers

1
BlackRock
BlackRock
New York
+$1.33M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$556K
3
State Street
State Street
Massachusetts
+$417K
4
Two Sigma Investments
Two Sigma Investments
New York
+$147K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
2
DWM
Destination Wealth Management
California
-$1.42M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
MHP
Manatuck Hill Partners
Connecticut
-$747K
5
LCM
Laurion Capital Management
New York
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
PK
101
Pflug Koory
Nebraska
$1K – – –
VIA
102
Vantage Investment Advisors
Pennsylvania
$1K – – –
NA
103
NewEdge Advisors
Louisiana
$41 -$10.9K -5,410 -19%
DWM
104
Destination Wealth Management
California
– -$1.42M -601,498 Closed
MHP
105
Manatuck Hill Partners
Connecticut
– -$747K -317,322 Closed
LCM
106
Laurion Capital Management
New York
– -$472K -200,458 Closed
Millennium Management
107
Millennium Management
New York
– -$305K -129,556 Closed
CAM
108
ClariVest Asset Management
California
– -$150K -64,467 Closed
AC
109
Ashler Capital
Illinois
– -$97K -41,239 Closed
GC
110
Guggenheim Capital
Illinois
– -$88K -37,290 Closed
Balyasny Asset Management
111
Balyasny Asset Management
Illinois
– -$81K -34,416 Closed
QSS
112
Quantitative Systematic Strategies
Florida
– -$52K -22,174 Closed
D.E. Shaw & Co
113
D.E. Shaw & Co
New York
– -$36K -15,386 Closed
PP
114
Paloma Partners
Connecticut
– -$34K -14,630 Closed
SG Americas Securities
115
SG Americas Securities
New York
– -$27K -11,555 Closed
IWM
116
IHT Wealth Management
Illinois
– -$21K -9,343 Closed
CMBA
117
C.M. Bidwell & Associates
Hawaii
– -$22K -9,310 Closed
SWP
118
Stratos Wealth Partners
Ohio
– -$14K -5,944 Closed
AIS
119
Accurate Investment Solutions
Pennsylvania
– -$3K -1,143 Closed
PA
120
Parallel Advisors
California
– +$630 +313 New
1 2 3 4
5

LCTX Hedge Fund Activity: Q2 2018 in Review

107 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2018, worth a combined $113M — down 25% from $152M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LCTX and 9 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $1.45M.

  • 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2018, down from 115 in Q1 2018.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
  • 9 funds opened new Lineage Cell Therapeutics positions in Q2 2018 and 17 closed out, a net change of -8 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.33M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $1.45M sold.

Based on aggregated 13F filings for Q2 2018.